Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2001;21:849-851

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liaugaudas, G.
Right arrow Articles by Bostom, A. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liaugaudas, G.
Right arrow Articles by Bostom, A. G.
Related Collections
Right arrow Nutrition
Right arrow Risk Factors
Right arrow Other arteriosclerosis
Right arrow Epidemiology
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2001;21:849.)
© 2001 American Heart Association, Inc.


Atherosclerosis and Lipoproteins

Renal Insufficiency, Vitamin B12 Status, and Population Attributable Risk for Mild Hyperhomocysteinemia Among Coronary Artery Disease Patients in the Era of Folic Acid–Fortified Cereal Grain Flour

Gintaras Liaugaudas1; Paul F. Jacques; Jacob Selhub; Irwin H. Rosenberg; Andrew G. Bostom

From the Division of General Internal Medicine (G.L., A.G.B.), Memorial Hospital of Rhode Island, Providence, and the Tufts Jean Mayer USDA Human Nutrition Research Center on Aging (P.F.J., J.S., I.H.R., A.G.B.), Boston, Mass.

Abstract—Fortification of enriched cereal grain flour products with folic acid has drastically reduced the prevalence of deficient plasma folate status, a major determinant of plasma total homocysteine (tHcy) levels. We hypothesized that even more liberally defined "suboptimal" plasma folate status might no longer contribute importantly to the population attributable risk (PAR) for mild hyperhomocysteinemia, a putative atherothrombotic risk factor. We determined fasting plasma tHcy, folate, vitamin B12, and pyridoxal 5'-phosphate levels, along with serum creatinine and albumin levels, in 267 consecutive patients (aged 61±9 [mean±SD] years, 76.4% men and 26.6% women) with stable coronary artery disease (CAD) who were nonusers of vitamin supplements or had abstained from supplement use for at least 6 weeks before examination. Subjects were evaluated a minimum of 3 months after the implementation of flour fortification was largely completed. Relative risk estimates for the calculation of PAR were derived from a multivariable-adjusted logistic regression model with >=12 µmol/L tHcy as the dependent variable and with age, sex, pyridoxal 5'-phosphate (continuous), albumin (continuous), <5 ng/mL folate, <250 pg/mL vitamin B12, and >=1.3 mg/dL creatinine as the independent variables. The prevalence of >=12 µmol/L plasma tHcy was 11.2% (30 of 267 patients). PAR estimates (percentage) for >=12 µmol/L tHcy were as follows: <5 ng/mL folate (<1%), <250 pg/mL vitamin B12 (24.5%), and >=1.3 mg/dL creatinine (37.5%). In the era of folic acid–fortified cereal grain flour, renal insufficiency and suboptimal vitamin B12 status (but not folate status) contribute importantly to the PAR for mild hyperhomocysteinemia among patients with stable CAD.


Key Words: coronary arteriosclerosis • renal function • homocysteine • determinants




This article has been cited by other articles:


Home page
Am. J. Clin. Nutr.Home page
L. Hoey, J. Strain, and H. McNulty
Studies of biomarker responses to intervention with vitamin B-12: a systematic review of randomized controlled trials
Am. J. Clinical Nutrition, June 1, 2009; 89(6): 1981S - 1996S.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
V. Ganji and M. R. Kafai
Demographic, Lifestyle, and Health Characteristics and Serum B Vitamin Status Are Determinants of Plasma Total Homocysteine Concentration in the Post-Folic Acid Fortification Period, 1999-2004
J. Nutr., February 1, 2009; 139(2): 345 - 352.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
L. Hoey, H. McNulty, N. Askin, A. Dunne, M. Ward, K. Pentieva, J. Strain, A. M Molloy, C. A Flynn, and J. M Scott
Effect of a voluntary food fortification policy on folate, related B vitamin status, and homocysteine in healthy adults
Am. J. Clinical Nutrition, November 1, 2007; 86(5): 1405 - 1413.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
J. Bleys, E. R Miller III, R. Pastor-Barriuso, L. J Appel, and E. Guallar
Vitamin-mineral supplementation and the progression of atherosclerosis: a meta-analysis of randomized controlled trials.
Am. J. Clinical Nutrition, October 1, 2006; 84(4): 880 - 887.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
H. McNulty, L. R. C. Dowey, J.J. Strain, A. Dunne, M. Ward, A. M. Molloy, L. B. McAnena, J. P. Hughes, M. Hannon-Fletcher, and J. M. Scott
Riboflavin Lowers Homocysteine in Individuals Homozygous for the MTHFR 677C->T Polymorphism
Circulation, January 3, 2006; 113(1): 74 - 80.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
W. Herrmann, H. Schorr, R. Obeid, and J. Geisel
Vitamin B-12 status, particularly holotranscobalamin II and methylmalonic acid concentrations, and hyperhomocysteinemia in vegetarians
Am. J. Clinical Nutrition, July 1, 2003; 78(1): 131 - 136.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Clin. Nutr.Home page
M. A. Johnson, N. A Hawthorne, W. R Brackett, J. G Fischer, E. W Gunter, R. H Allen, and S. P Stabler
Hyperhomocysteinemia and vitamin B-12 deficiency in elderly using Title IIIc nutrition services
Am. J. Clinical Nutrition, January 1, 2003; 77(1): 211 - 220.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
R. Carmel, R. Green, D. S. Rosenblatt, and D. Watkins
Update on Cobalamin, Folate, and Homocysteine
Hematology, January 1, 2003; 2003(1): 62 - 81.
[Abstract] [Full Text] [PDF]


Home page
Vasc MedHome page
N. Weiss, C. Keller, U. Hoffmann, and J. Loscalzo
Endothelial dysfunction and atherothrombosis in mild hyperhomocysteinemia
Vascular Medicine, August 1, 2002; 7(3): 227 - 239.
[Abstract] [PDF]


Home page
NEJMHome page
D. V. Chirieac, T. A. Pearson, A. G. Bostom, B. Sharaf, N. Miele, G. Schnyder, and Z. G. Turi
B Vitamins and Restenosis after Coronary Angioplasty
N. Engl. J. Med., April 4, 2002; 346(14): 1093 - 1095.
[Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
A. G. Bostom, P. F. Jacques, G. Liaugaudas, G. Rogers, I. H. Rosenberg, and J. Selhub
Total Homocysteine Lowering Treatment Among Coronary Artery Disease Patients in the Era of Folic Acid-Fortified Cereal Grain Flour
Arterioscler. Thromb. Vasc. Biol., March 1, 2002; 22(3): 488 - 491.
[Abstract] [Full Text] [PDF]